|
T9305 |
Necroptosis-IN-1
|
|
RIP kinase
|
|
Necroptosis-IN-1 is a potent necroptosis inhibitor of RIPK1. It is an analog of Necrostatin-1. |
|
T64349 |
Necroptosis-IN-3
|
Cyclohexanecarboxamide, N-(2-thienylmethyl)- |
Necroptosis
|
|
Necroptosis-IN-3 (Cyclohexanecarboxamide, N-(2-thienylmethyl)-) (Compound 69) is a Necroptosis inhibitor that inhibits TNF-α induced necroptosis. Necroptosis-IN-3 (Compound STX1638) also inhibits 11β-HSD1. |
|
T9465 |
ZZW-115 hydrochloride
|
|
Apoptosis
,
Others
|
|
ZZW-115 hydrochloride inhibits the activity of NUPR1. |
|
T9079 |
Apostatin-1
|
Apt-1 |
Others
|
|
Apostatin-1 (Apt-1) is a novel TRADD inhibitor. Apostatin-1 can bind to a pocket on the N-terminal TRAF2 binding domain of TRADD. |
|
T9095 |
Necrostatin-34
|
2-{[3-cyano-4-(4-methylphenyl)-6-oxo-1,4 |
RIP kinase
|
|
Necrostatin-34 (2-{[3-cyano-4-(4-methylphenyl)-6-oxo-1,4) is a RIPK1 kinase inhibitor, stabilizing RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain. |
|
T7504 |
Necrostatin 2 racemate
|
Necrostatin-2 racemate |
RIP kinase
|
|
Necrostatin 2 racemate (Necrostatin-2 racemate) is an potent and specific inhibitor of RIPK1. |
|
T13603 |
CDDO-3P-Im
|
|
Necroptosis
|
|
CDDO-3P-Im is an orally active inhibitor of necroptosis with chemopreventive effects. CDDO-3P-Im can be used in studies about ischemia/reperfusion. |
|
T11520 |
GW806742X
|
|
MLK
,
VEGFR
|
|
GW806742X is an inhibitor of Mixed Lineage Kinase Domain-Like protein (MLKL) which binds the MLKL pseudokinase domain (Kd: 9.3 μM) with anti-necroptosis activity. GW806742X has activity against VEGFR2. |
|
T9429 |
ZZW-115
|
|
|
|
ZZW-115 is a potent NUPR1 inhibitor with a Kd of 2.1 μM. ZZW-115 is a derivative of Trifluoperazine (TFP). ZZW-115 shows a dose-dependent tumor regression with no neurological side effects and induces cell death mainly b... |
|
T6904 |
Necrosulfonamide
|
(E)-Necrosulfonamide |
MLK
|
|
(E)-Necrosulfonamide ((E)-Necrosulfonamide) is an inhibitor of necroptosis. Blocks mixed lineage kinase domain-like protein (MLKL), a critical substrate of receptor-interacting serine-threonine kinase 3 (RIP3) during nec... |
|
T37558 |
Necrostatin-5
|
Nec-5 |
RIP kinase
,
Necroptosis
|
|
Necrostatin-5 (Nec-5) is a selective inhibitor of RIP1 kinase and a cell necrosis inhibitor that prevents the death of Fadd-deficient Jurkat cells treated with TNF-α with an EC50 value of 240 nM. |
|
T12203L |
Necrostatin 2
|
|
Others
|
|
|
|
T79347 |
Anticancer agent 146
|
|
Necroptosis
|
|
Anticancer Agent 146 (Compound 1.19) acts as a necroptosis inducer and demonstrates anti-tumor efficacy in the MDA-MB-231 mouse xenograft model [1]. |
|
T81267 |
RIPK3-IN-4
|
|
RIP kinase
|
|
RIPK3-IN-4 (Compound 42) is a RIPK3 inhibitor that mitigates necroptosis, inflammatory responses, and HK-2 cell damage. It alleviates acute kidney injury by attenuating Cisplatin- and I/R-induced kidney damage, along wit... |
|
T40330 |
Anticancer agent 15
|
|
|
|
Anticancer agent 15, an anticancer agent, exerts its efficacy by elevating intracellular levels of reactive oxygen species (ROS) and inducing cell death in melanoma cancer cells through necroptosis. |
|
T73279 |
MLKL-IN-5
|
|
|
|
MLKL-IN-5 is a potent MLKL inhibitor that mediates necroptosis . |
|
T71998 |
673-A
|
|
|
|
673-A is an aldehyde dehydrogenase (ALDH1A) inhibitor that depletes CD133+ cancer stem cells (CSC) in ovarian cancer cell lines. 673-A triggers necroptosis in ovarian CSCs and induces expression of mitochondrial uncoupli... |
|
T81268 |
RIPK1-IN-17
|
|
RIP kinase
|
|
RIPK1/3-IN-1 (Compound 10) is a selective inhibitor of both RIPK1 and RIPK3, effectively preventing necroptosis by blocking the phosphorylation of RIPK1, RIPK3, and MLKL [1]. |
|
T80052 |
Cathepsin B
|
|
|
|
Cathepsin B, a cysteine protease, plays a role in various forms of programmed cell death, such as apoptosis, pyroptosis, ferroptosis, necroptosis, and autophagic cell death [1]. |
|
T81269 |
RIPK1-IN-16
|
|
RIP kinase
|
|
RIPK1-IN-16 is an orally active, potent RIPK1 inhibitor that mitigates excessive inflammation via inhibition of RIPK1-mediated necroptosis in vivo. It shields mice from TNF-induced systemic inflammatory response syndrome... |
|
T62723 |
RIPK1-IN-12
|
|
|
|
RIPK1-IN-12 is a potent inhibitor of RIPK1, which exhibits an inhibitory effect on necroptosis in human and mouse cells with EC50 values of 1.6 and 2.9 nM, respectively. |
|
T79369 |
ZMF-23
|
|
PAK
|
|
ZMF-23, a PAK1/HDAC6 dual inhibitor, suppresses PAK1 and HDAC6-mediated aerobic glycolysis and cellular migration while inducing TNF-α-regulated necroptosis and augmenting apoptosis. The compound effectively hampers the ... |
|
T79831 |
PROTAC MLKL Degrader-1
|
|
|
|
PROTAC MLKL Degrader-1 (Compound 36) is a selective PROTAC degrader targeting MLKL, achieving a degradation maximum (D max) over 90%. The compound encompasses modified cereblon (CRBN) ligands and a lenalidomide-linker as... |
|
T78784 |
RIPK3-IN-3
|
|
|
|
RIPK3-IN-3 (compound 20) is a selective RIPK3 inhibitor that demonstrates potent activity with an IC50 value of 10 nM. This compound effectively blocks RIPK3-mediated phosphorylation of MLKL, preventing its oligomerizati... |
|
T74681 |
NecroIr2
|
|
|
|
NecroIr2, an iridium(III) complex, functions as a necroptosis inducer in cisplatin-resistant lung cancer cells (A549R). It preferentially accumulates in mitochondria, causing oxidative stress and a reduction in mitochond... |
|
T37851 |
Chlorido[N,N'-disalicylidene-1,2-phenylenediamine]iron(III)
|
|
|
|
Chlorido[N,N'-disalicylidene-1,2-phenylenediamine]iron(III) is an inducer of ferroptosis.1 It induces ferroptosis, but not apoptosis or necroptosis, in NB1 cancer cells when used at a concentration of 3 μM.1 Chlorido[N,N... |
|
T74680 |
NecroIr1
|
|
|
|
NecroIr1, an iridium(III) complex, acts as a necroptosis inducer in Cisplatin-resistant lung cancer cells (A549R). It selectively targets mitochondria, causing oxidative stress and reducing mitochondrial membrane potenti... |
|
T73382 |
SZM-1209
|
|
RIP kinase
|
|
SZM-1209 is a potent and specific RIPK1 inhibitor with oral activity, displaying a dissociation constant (Kd) of 85 nM. It demonstrates substantial anti-necroptotic efficacy with an EC50 of 22.4 ± 8.1 nM and possesses th... |
